Japan-Wide Clinical Trial Network

Pricing Reform

Increased pricing for innovative drugs to encourage global development

Accelerated Approval

Easing of the historical delays often associated with drug approval in country

Waived Requirements

Global phase III trials no longer require a domestic phase I trial prior to Japanese enrollment

Globalization

>50% of clinical trials in Japan are a part of a global research program, and the trend is expected to rise

NCC will Initiate New Research to Develop a Nationwide Clinical Trial Network, LC-SCRUM-CD (Clinical Development), Supported by PREMIA and Paradigm, to Further Accelerate Precision Medicine for Cancer Patients

Together, these organizations will work to bring more global pharmaceutical-sponsored clinical trials to Japan and to accelerate clinical trial patient enrollment by simplifying the systems and workflows in current clinical trials. This effort will reduce the cost and time required of physicians and hospitals staff to conduct clinical trials, while expanding patients’ access to clinical trials, an option for cancer care. Read more
 

Paradigm Partners with Fujitsu to Solve Clinical Trials in Japan

"When I founded Paradigm it was with a similar vision to what Fujitsu is solving with Uvance Healthy Living - that every single patient should have access to the best possible care for their disease inclusive of a clinical trial as a care option," said Kent Thoelke, Chief Executive Officer, Paradigm. "No patient should lack the access to these treatment options as a result of where they live, their ethnic background, their socioeconomic status, or the physician or medical institution where they are being treated. This includes the disparities created by the drug loss problem created by global clinical trial development strategies." Read more
 

Fujitsu Tackles ‘Drug Loss’ in Japan Through Ecosystem to Accelerate Digitalization of Clinical Trials

Kawasaki, August 26, 2024 - Fujitsu today announced that it will begin initiatives to attract global clinical trials to Japan and tackle the “Drug Loss” by working with pharmaceutical companies and medical institutions to build a new medical data ecosystem. The efforts come under the Fujitsu Uvance Healthy Living, which aims to improve people’s well-being. In July 2024, Fujitsu executed a strategic partnership agreement with Paradigm Health, Inc., a US startup that provides one of the world’s most advanced clinical trial platforms. Through utilizing this platform, Fujitsu’s Healthy Living Platform, and the Fujitsu Kozuchi AI service, Fujitsu and Paradigm will facilitate the collection and processing of data stored at medical institutions and speed up the clinical trial planning process. Read more